top of page

Incyte CEO Hervé Hoppenot on axatilimab for GvHD, BET inhibition, oral PD-1s and more from #ASH23

Hervé Hoppenot discusses Incyte's #ASH23 presentations, the company's pipeline, success in dermatology, and how he thinks about Jakafi's future.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page